The differecnces between SGLT2 and DPP4 inhibitors in blood glucose management and cardiac sympathetic nerve activity
Not Applicable
Completed
- Conditions
- Diabetes mellitus (DM) patients complicated with heart failure (HF)
- Registration Number
- JPRN-UMIN000032277
- Lead Sponsor
- Toho University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnancy, breast-feeding, patients who may be pregnant, and patients who want pregnancy during the study Patients who may be thought to worse blood glucose management with the protocol of this study Patients with moderate or severe renal impairment (less than eGFR45) Patients with severe hepatic impairment (Child-Pugh classification C) Patients who were judged inappropriate as subjects of this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood glucose management
- Secondary Outcome Measures
Name Time Method cardiac sympathetic nerve activity
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate SGLT2 and DPP4 inhibitors in managing diabetes and heart failure?
How do SGLT2 and DPP4 inhibitors compare in their effects on cardiac sympathetic nerve activity in DM patients with HF?
What biomarkers could predict differential response to SGLT2 versus DPP4 inhibitors in diabetic heart failure patients?
What are the known adverse event profiles of SGLT2 and DPP4 inhibitors in heart failure populations?
Are there combination therapies involving SGLT2 and DPP4 inhibitors that improve glycemic control and cardiac outcomes in DM with HF?